What is a stock summary page? Click here for an overview.
Business Description

Aspen Pharmacare Holdings Ltd
ISIN : ZAE000066692
Compare
Compare
Traded in other countries / regions
APN.South AfricaAPNHY.USALDZU.Germany IPO Date
2006-06-28Description
Aspen Pharmacare Holdings Ltd is a specialty pharmaceutical company with a commercial footprint covering more than 50 countries and complex manufacturing capabilities in both API and finished dose form. The company focuses on a broad range of post-patent, branded medicines and domestic brands spanning many therapeutic areas. The company has four business segments such as Active Pharmaceutical Ingredients (API) this segment includes the API Chemicals business and non-heparin biochemical API business, Heparin segment includes the full value chain contribution from all heparin containing products including API and Finished Dose. Form (FDF) sales Key products include the Fraxiparine and MonoEmbolex heparin containing FDF products and FDF Steriles segment.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.19 | |||||
Equity-to-Asset | 0.62 | |||||
Debt-to-Equity | 0.42 | |||||
Debt-to-EBITDA | 4.42 | |||||
Interest Coverage | 3.82 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 2.03 | |||||
Beneish M-Score | -2.53 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 6.8 | |||||
3-Year EBITDA Growth Rate | 4.8 | |||||
3-Year EPS without NRI Growth Rate | 4.4 | |||||
3-Year FCF Growth Rate | -40.7 | |||||
3-Year Book Growth Rate | 9.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 12.73 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 7.39 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 57.47 | |||||
9-Day RSI | 44.3 | |||||
14-Day RSI | 40.25 | |||||
3-1 Month Momentum % | 6.47 | |||||
6-1 Month Momentum % | -9.05 | |||||
12-1 Month Momentum % | -16.97 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.35 | |||||
Quick Ratio | 1.25 | |||||
Cash Ratio | 0.39 | |||||
Days Inventory | 272.46 | |||||
Days Sales Outstanding | 96.73 | |||||
Days Payable | 121.01 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 2.5 | |||||
Dividend Payout Ratio | 0.24 | |||||
Forward Dividend Yield % | 2.5 | |||||
5-Year Yield-on-Cost % | 2.52 | |||||
3-Year Average Share Buyback Ratio | 0.8 | |||||
Shareholder Yield % | -2.41 |
Profitability Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 45.24 | |||||
Operating Margin % | 17.04 | |||||
Net Margin % | 9.84 | |||||
FCF Margin % | 0.44 | |||||
ROE % | 5.26 | |||||
ROA % | 3.24 | |||||
ROIC % | 4.9 | |||||
3-Year ROIIC % | -6.86 | |||||
ROC (Joel Greenblatt) % | 19.91 | |||||
ROCE % | 6.87 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 14.85 | |||||
Forward PE Ratio | 7.21 | |||||
PE Ratio without NRI | 9.8 | |||||
Shiller PE Ratio | 10.22 | |||||
Price-to-Owner-Earnings | 18.52 | |||||
PEG Ratio | 0.85 | |||||
PS Ratio | 1.46 | |||||
PB Ratio | 0.78 | |||||
Price-to-Tangible-Book | 5.57 | |||||
Price-to-Free-Cash-Flow | 282.05 | |||||
Price-to-Operating-Cash-Flow | 11.94 | |||||
EV-to-EBIT | 12.55 | |||||
EV-to-EBITDA | 12.55 | |||||
EV-to-Revenue | 2.22 | |||||
EV-to-FCF | 403.39 | |||||
Price-to-GF-Value | 0.65 | |||||
Price-to-Projected-FCF | 0.78 | |||||
Price-to-Median-PS-Value | 0.66 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.93 | |||||
Price-to-Graham-Number | 1.6 | |||||
Earnings Yield (Greenblatt) % | 7.96 | |||||
FCF Yield % | 0.33 | |||||
Forward Rate of Return (Yacktman) % | 15.73 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aspen Pharmacare Holdings Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 2,339.044 | ||
EPS (TTM) (€) | 0.519 | ||
Beta | 1.22 | ||
3-Year Sharpe Ratio | -0.29 | ||
3-Year Sortino Ratio | -0.41 | ||
Volatility % | 22.62 | ||
14-Day RSI | 40.25 | ||
14-Day ATR (€) | 0.195254 | ||
20-Day SMA (€) | 7.8175 | ||
12-1 Month Momentum % | -16.97 | ||
52-Week Range (€) | 6.7 - 12.7 | ||
Shares Outstanding (Mil) | 444.23 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Aspen Pharmacare Holdings Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Aspen Pharmacare Holdings Ltd Stock Events
Event | Date | Price (€) | ||
---|---|---|---|---|
No Event Data |
Aspen Pharmacare Holdings Ltd Frequently Asked Questions
What is Aspen Pharmacare Holdings Ltd(FRA:LDZA)'s stock price today?
The current price of FRA:LDZA is €7.35. The 52 week high of FRA:LDZA is €12.70 and 52 week low is €6.70.
When is next earnings date of Aspen Pharmacare Holdings Ltd(FRA:LDZA)?
The next earnings date of Aspen Pharmacare Holdings Ltd(FRA:LDZA) is .
Does Aspen Pharmacare Holdings Ltd(FRA:LDZA) pay dividends? If so, how much?
The Dividend Yield %  of Aspen Pharmacare Holdings Ltd(FRA:LDZA) is 2.5% (As of Today), Highest Dividend Payout Ratio of Aspen Pharmacare Holdings Ltd(FRA:LDZA) was 0.24. The lowest was 0.15. And the median was 0.18. The  Forward Dividend Yield % of Aspen Pharmacare Holdings Ltd(FRA:LDZA) is 2.5%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |